UA101339C2 - Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных - Google Patents
Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производныхInfo
- Publication number
- UA101339C2 UA101339C2 UAA201006372A UAA201006372A UA101339C2 UA 101339 C2 UA101339 C2 UA 101339C2 UA A201006372 A UAA201006372 A UA A201006372A UA A201006372 A UAA201006372 A UA A201006372A UA 101339 C2 UA101339 C2 UA 101339C2
- Authority
- UA
- Ukraine
- Prior art keywords
- colorectal
- prevention
- treatment
- diseases
- colorectal cancer
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- ZXBCLVSLRUWISJ-UHFFFAOYSA-N 2-methyl-1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine Chemical compound C1=CC=NC2=C3N(CC(C)C)C(C)=NC3=C(N)N=C21 ZXBCLVSLRUWISJ-UHFFFAOYSA-N 0.000 abstract 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 abstract 2
- 241000565118 Cordylophora caspia Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000037062 Polyps Diseases 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 abstract 1
- 229940124669 imidazoquinoline Drugs 0.000 abstract 1
- 229960002751 imiquimod Drugs 0.000 abstract 1
- 229940124622 immune-modulator drug Drugs 0.000 abstract 1
- 229950010550 resiquimod Drugs 0.000 abstract 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 abstract 1
- 229950008380 sotirimod Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US645908P | 2008-01-15 | 2008-01-15 | |
| PCT/EP2008/011088 WO2009089900A1 (en) | 2008-01-15 | 2008-12-23 | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA101339C2 true UA101339C2 (ru) | 2013-03-25 |
Family
ID=40419193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201006372A UA101339C2 (ru) | 2008-01-15 | 2008-12-23 | Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8008319B2 (enExample) |
| EP (1) | EP2237780A1 (enExample) |
| JP (1) | JP2011509956A (enExample) |
| CN (1) | CN101909624A (enExample) |
| AU (1) | AU2008347400B2 (enExample) |
| BR (1) | BRPI0822002A2 (enExample) |
| CA (1) | CA2708559C (enExample) |
| EA (1) | EA018579B1 (enExample) |
| GE (1) | GEP20125605B (enExample) |
| IL (1) | IL205819A (enExample) |
| MX (1) | MX2010007699A (enExample) |
| NZ (1) | NZ586161A (enExample) |
| UA (1) | UA101339C2 (enExample) |
| WO (1) | WO2009089900A1 (enExample) |
| ZA (1) | ZA201003906B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
| CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CA3067268A1 (en) * | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Crystalline resiquimod monosulfate anhydrate and its preparation and uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2078547C1 (ru) * | 1995-11-28 | 1997-05-10 | Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ | Способ лечения полипоза желудка и двенадцатиперстной кишки |
| UA75622C2 (en) * | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US20040092583A1 (en) * | 2001-01-02 | 2004-05-13 | Elizabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
| BRPI0416801A (pt) * | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
-
2008
- 2008-12-23 WO PCT/EP2008/011088 patent/WO2009089900A1/en not_active Ceased
- 2008-12-23 JP JP2010542534A patent/JP2011509956A/ja active Pending
- 2008-12-23 AU AU2008347400A patent/AU2008347400B2/en not_active Ceased
- 2008-12-23 MX MX2010007699A patent/MX2010007699A/es active IP Right Grant
- 2008-12-23 BR BRPI0822002A patent/BRPI0822002A2/pt not_active IP Right Cessation
- 2008-12-23 GE GEAP200811913A patent/GEP20125605B/en unknown
- 2008-12-23 EA EA201001164A patent/EA018579B1/ru not_active IP Right Cessation
- 2008-12-23 CA CA2708559A patent/CA2708559C/en not_active Expired - Fee Related
- 2008-12-23 UA UAA201006372A patent/UA101339C2/ru unknown
- 2008-12-23 NZ NZ586161A patent/NZ586161A/en unknown
- 2008-12-23 CN CN2008801223531A patent/CN101909624A/zh active Pending
- 2008-12-23 EP EP08871156A patent/EP2237780A1/en not_active Withdrawn
-
2009
- 2009-01-14 US US12/353,683 patent/US8008319B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 IL IL205819A patent/IL205819A/en not_active IP Right Cessation
- 2010-06-01 ZA ZA2010/03906A patent/ZA201003906B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0822002A2 (pt) | 2015-10-13 |
| WO2009089900A1 (en) | 2009-07-23 |
| MX2010007699A (es) | 2010-08-04 |
| NZ586161A (en) | 2012-05-25 |
| CA2708559C (en) | 2015-10-06 |
| EA018579B1 (ru) | 2013-09-30 |
| GEP20125605B (en) | 2012-08-10 |
| JP2011509956A (ja) | 2011-03-31 |
| EP2237780A1 (en) | 2010-10-13 |
| IL205819A0 (en) | 2010-11-30 |
| EA201001164A1 (ru) | 2010-12-30 |
| ZA201003906B (en) | 2011-03-30 |
| AU2008347400A1 (en) | 2009-07-23 |
| US8008319B2 (en) | 2011-08-30 |
| CA2708559A1 (en) | 2009-07-23 |
| IL205819A (en) | 2013-02-28 |
| AU2008347400B2 (en) | 2014-12-11 |
| US20090182005A1 (en) | 2009-07-16 |
| CN101909624A (zh) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA101339C2 (ru) | Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных | |
| MX350597B (es) | 4- (8 - metoxi - 1 - ( (1 - metoxipropan - 2 - il) - 2 - (tetrahidro - 2h - piran - 4 - il) - 1 h - imidazo [4,5-c] quinolin -7 - il ) -3,5 - dimetilisoxazol y su uso como inhibidor de bromodominio. | |
| EP4140487A8 (en) | Combination therapy for treating cancer | |
| PH12014500867A1 (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases | |
| WO2012143416A3 (en) | 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives | |
| TN2013000237A1 (en) | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor | |
| IN2014MN02049A (enExample) | ||
| PH12012500497A1 (en) | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
| UA118645C2 (uk) | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| TNSN07193A1 (en) | Pharmaceutical compositions comprising a camptothecin derivate | |
| IN2014MN00987A (enExample) | ||
| WO2014062720A3 (en) | Methods of treating cancer | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| WO2012054748A3 (en) | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| TR201907590T4 (tr) | Ssao inhibitörleri olarak imidazo[4,5-c]piridin ve pirrolo[2,3-c]piridin türevleri. | |
| WO2012171015A3 (en) | Therapeutic combination for cancer treatment | |
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| MY150747A (en) | Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| CR20120068A (es) | Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales | |
| WO2009087091A8 (en) | Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy | |
| GEP20135818B (en) | Nitrogenated derivatives of pancratistatin |